Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 1133-1137

  Lee, Christine C ^a   McMillin, Gwendolyn A ^b   Babic, Nikolina ^a   Melis, Roberta ^b   Yeo, Kiang Teck J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

Clopidogrel; CYP2C19; Cytochrome P450; Pharmacogenomics

Indexed keywords

CYTOCHROME P450 2C19; REAGENT;

ALLELE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ASSAY; ENZYMIC BIOSENSOR; GENETIC VARIABILITY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CELL LINE; GENOMICS; GENOTYPING TECHNIQUES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79955014308     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.001     Document Type: Article

References (26)

1. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
2. Gladding P., White H., Voss J., et al. Pharmacogenetic testing for clopidogrel using the rapid infiniti analyzer: a dose-escalation study. JACC Cardiovasc Intervent 2009, 2:1095-1101.
3. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
4. Mega J.L., Simon T., Collet J.-P., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
5. Savi P., Herbert J.M., Pflieger A.M., et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992, 44:527-532.
6. Ellis K.J., Stouffer G.A., McLeod H.L., Lee C.R. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenom 2009, 10:1799-1817.
7. Freedman J.E., Hylek E.M. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009, 360:411-413.
8. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
9. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51:1925-1934.
10. Hulot J.-S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
11. Pare G., Mehta S.R., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
12. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
13. Robarge J.D., Li L., Desta Z., Nguyen A., Flockhart D.A. The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther 2007, 82:244-248.
14. Alain L.-W.-P., Thierry G., Peter F., Candy C., James L. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 17. Br J Clin Pharmacol 2009, 69:222-230.
15. Li-Wan-Po A., Girard T., Farndon P., Cooley C., Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 17. Br J Clin Phamacol 2010, 69:222-230.
16. Goldstein J.A., Ishizaki T., Chiba K., et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7:59-64.
17. Pratt V.M., Zehnbauer B., Wilson J.A., et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology Collaborative Project. J Mol Diagn 2010, 12:835-846.
18. Babic N., Haverfield E.V., Burrus J.A., Lozada A., Das S., Yeo K.-T.J. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta 2009, 406:143-147.
19. LE Melis R., McMillin G.A. Cytochrome P450 genotyping by Tag-It. Expert Rev Mol Diag 2006, 6:811-820.
20. Jin B., Ni H.-C., Shen W., Li J., Shi H.-M., Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2010, 1-6.
21. FDA announces new boxed warning on Plavix: alerts patients, health care professionals to potential for reduced effectiveness http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204253.htm.
22. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121:512-518.
23. Mega J.L., Close S.L., Wiviott S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. ancet 2010, 376:1312-1319.
24. Wu A.H.B., Babic N., Yeo K.-T.J. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Pers Medi 2009, 6:315-327.
25. Gurbel P.A., Tantry U.S., Shuldiner A.R., Kereiakes D.J. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010, 56:112-116.
26. Damani S.B., Topol E.J. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol 2010, 56:109-111.